- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04170439
Added Value of N Acetyle Cysteine to Clomiphene Citrate in PCO
April 26, 2021 updated by: Mahmoud Alalfy, Aljazeera Hospital
The Added Value of n Acetyle Cysteine and Chromium to Clomiphene Citrate in PCO
PCO is one of the factors associated with delayed conception
Study Overview
Status
Completed
Conditions
Detailed Description
In an attempt to induce ovulation Clomiphene citrate can be given in conjunction with N acetyle cysteine
Study Type
Interventional
Enrollment (Actual)
108
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Giza, Egypt
- Algazeerah and Kasralainy hospital
-
Giza, Egypt
- Algazeerah
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- women with PCO
Exclusion Criteria:
- women who donot have PCO
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: clomiphene plus metformin plus N acetyle cysteine
Women who will receive clomiphene citrate plus metformin plus n acetyle cysteine
|
oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
|
Other: clomiphene plus metformin plus chromium
Women who will receive clomiphene plus metformin plus chromium
|
oral adminstration of clomiphene citrate plus metformin and chromium
|
Other: clomiphen citrate plus metformin
Women who will receive clomiphene plus metformin
|
oral adminstration of clomiphene citrate plus metformin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of women who will have mature follicles wih their size and number of mqture follicles The number of women who will have mature follicles
Time Frame: within 2 weeks
|
Assessment of women in both groups for size and number of follicles
|
within 2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Mahmoud Alalfy, PhD, Algezeera
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2019
Primary Completion (Actual)
May 2, 2020
Study Completion (Actual)
May 15, 2020
Study Registration Dates
First Submitted
November 16, 2019
First Submitted That Met QC Criteria
November 19, 2019
First Posted (Actual)
November 20, 2019
Study Record Updates
Last Update Posted (Actual)
April 28, 2021
Last Update Submitted That Met QC Criteria
April 26, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Trace Elements
- Micronutrients
- Hormone Antagonists
- Anticoagulants
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Chelating Agents
- Sequestering Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Calcium Chelating Agents
- Metformin
- Citric Acid
- Sodium Citrate
- Chromium
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
- chromium in infertility
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PCO
-
Beni-Suef UniversityNot yet recruiting
-
Beni-Suef UniversityRecruiting
-
American University of Beirut Medical CenterActive, not recruitingInfertility | PCO - Polycystic OvariesLebanon
-
Royan InstituteCompletedPCOIran, Islamic Republic of
-
Ain Shams Maternity HospitalRecruitingPCO | Clomiphene Citrate | Induction of OvulationEgypt
-
Cairo UniversityCompletedAcupuncture | PCO | Primary Hypothyroidism | Irregular MenstruationEgypt
-
Riphah International UniversityNot yet recruiting
-
Khyber Medical University PeshawarCompleted
Clinical Trials on Clomiphene plus metformin plus N acetyle cysteine in arm number 1
-
Woman'sAstraZenecaCompletedEQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)Obesity | Polycystic Ovary SyndromeUnited States
-
Sun Yat-sen UniversityNovo Nordisk A/S; Hoffmann-La Roche; Ministry of Education, China; Guangdong Science...CompletedType 2 Diabetes MellitusChina
-
James Backes, PharmDMarcor Development CorporationCompletedHigh CholesterolUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedCardiovascular Diseases | Coronary Disease | Hypertension | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Atherosclerosis | HypercholesterolemiaUnited States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingExtraocular RetinoblastomaUnited States, Canada, Australia, Brazil, Argentina, Egypt
-
National Cancer Institute (NCI)Active, not recruitingGanglioneuroblastoma | High Risk NeuroblastomaUnited States, New Zealand, Australia
-
National Cancer Institute (NCI)Not yet recruitingNeuroblastoma | Ganglioneuroblastoma